Halozyme Therapeutics, Inc.  

(Public, NASDAQ:HALO)   Watch this stock  
Find more results for HALO
16.68
+0.26 (1.58%)
After Hours: 16.61 -0.07 (-0.42%)
Sep 20, 6:06PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.40 - 17.08
52 week 8.18 - 17.55
Open 16.52
Vol / Avg. 0.00/1.60M
Mkt cap 2.37B
P/E     -
Div/yield     -
EPS -0.92
Shares 141.92M
Beta 2.28
Inst. own 88%
Nov 6, 2017
Q3 2017 Halozyme Therapeutics Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 26, 2017
Halozyme Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference - 8:35AM EDT - Add to calendar
Sep 7, 2017
Halozyme Therapeutics Inc at Wells Fargo Healthcare Conference
Aug 10, 2017
Halozyme Therapeutics Inc at Canaccord Genuity Growth Conference - Webcast
Aug 8, 2017
Q2 2017 Halozyme Therapeutics Inc Earnings Call - Webcast
Aug 8, 2017
Q2 2017 Halozyme Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -91.15% -70.23%
Operating margin -75.49% -56.72%
EBITD margin - -55.08%
Return on average assets -43.18% -46.48%
Return on average equity - -1958.98%
Employees 259 -
CDP Score - -

Address

11388 Sorrento Valley Rd
SAN DIEGO, CA 92121-1345
United States - Map
+1-858-7948889 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Officers and directors

Connie L. Matsui Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Helen I Torley President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Laurie D. Stelzer Chief Financial Officer, Senior Vice President
Age: 49
Bio & Compensation  - Reuters
Mark J. Gergen J.D. Chief Operating Officer, Senior Vice President
Age: 54
Bio & Compensation  - Reuters
Harry J. Leonhardt Esq. Senior Vice President, Chief Compliance Officer, General Counsel
Age: 60
Bio & Compensation  - Reuters
Athena M. Countouriotis M.D. Senior Vice President, Chief Medical Officer
Age: 45
Bio & Compensation  - Reuters
Jean-Pierre Bizzari M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
James M. Daly Independent Director
Age: 55
Bio & Compensation  - Reuters
Jeffrey William Henderson Independent Director
Age: 52
Bio & Compensation  - Reuters
Kenneth J. Kelley Independent Director
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance